Quick View
| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥482.6B | ¥466.6B | +3.4% |
| Operating Income | ¥23.7B | ¥36.3B | −34.8% |
| Ordinary Income | ¥22.2B | ¥33.4B | −33.7% |
| Net Income | ¥16.8B | ¥24.0B | −29.9% |
| ROE | 4.9% | 7.3% | - |
Executive Summary
FY2025 Q3 results show revenue of 482.6B yen (YoY +3.4%) with operating income of 23.7B yen (YoY -34.8%), ordinary income of 22.2B yen (YoY -33.7%), and net income of 16.8B yen (YoY -29.9%). While top-line growth remained steady at +3.4%, profitability deteriorated sharply with operating margin contracting to 4.9% from prior year's 7.8%, a decline of 289 basis points. The profit decline was driven primarily by SG&A expense expansion to 101.5B yen (21.0% of revenue), overshadowing stable gross profit margin of 25.9%. Short-term borrowings surged 46.7% YoY to 276.2B yen, raising liquidity concerns as cash-to-short-term-debt coverage stands at 0.25x with cash and deposits of 68.8B yen.
Performance Drivers
Revenue increased 3.4% YoY to 482.6B yen, demonstrating continued top-line momentum. Cost of sales rose to 357.4B yen, resulting in gross profit of 125.2B yen at a stable margin of 25.9%, unchanged from the prior period. However, SG&A expenses expanded significantly to 101.5B yen (21.0% of revenue), representing a material increase from the prior year's implied SG&A ratio. This cost base expansion drove operating income down 34.8% to 23.7B yen, compressing operating margin from 7.8% to 4.9%. Non-operating items contributed modestly negative with financial costs increasing alongside borrowing growth, leading to ordinary income of 22.2B yen, down 33.7% YoY. The gap between ordinary income (22.2B yen) and net income (16.8B yen) reflects a tax burden ratio of 73.0%, consistent with normal taxation without material extraordinary items. This represents a revenue up/profit down pattern, where modest sales growth was overwhelmed by operational cost expansion and resulting margin compression.
Key Metrics
[Profitability] ROE of 4.9% declined from prior levels, driven by net profit margin compression to 3.5% (calculated as 16.8B yen net income divided by 482.6B yen revenue). Operating margin of 4.9% contracted 289 basis points from 7.8% in the prior year, reflecting SG&A expense growth outpacing revenue expansion. Gross profit margin held steady at 25.9%. [Cash Quality] Cash and deposits of 68.8B yen provide 0.25x coverage of short-term borrowings at 276.2B yen, indicating constrained liquidity. Working capital stands at 56.6B yen but is characterized by elevated receivables of 251.0B yen and inventories of 122.4B yen, suggesting extended operating cycles. [Investment Efficiency] Total asset turnover of 0.540x reflects moderate asset utilization, while ROIC estimated at approximately 3.0% indicates room for improvement in capital efficiency. [Financial Health] Equity ratio of 38.7% (346.6B yen equity against 894.5B yen total assets) and current ratio of 111.1% (566.4B yen current assets against 509.8B yen current liabilities) provide baseline financial stability, though debt-to-equity of 1.58x and concentration of 92.9% of interest-bearing debt in short-term maturities warrant monitoring.
Cash Flow Analysis
Cash and deposits of 68.8B yen face pressure from elevated working capital requirements, with accounts receivable at 251.0B yen and inventories at 122.4B yen representing significant capital tied up in operations. Short-term borrowings increased 87.9B yen YoY to 276.2B yen, a 46.7% surge, indicating external financing to support working capital needs or operational requirements. The cash-to-short-term-debt ratio of 0.25x highlights immediate refinancing risk, as current cash holdings cover only one-quarter of near-term debt obligations. Long-term loans of 21.0B yen represent 7.1% of total interest-bearing debt, indicating heavy reliance on short-term funding. The expansion in current liabilities to 509.8B yen reflects both increased borrowings and trade payables, with electronically recorded obligations comprising 40.0B yen. Working capital efficiency shows strain with extended receivables and inventory turnover cycles, constraining organic cash generation despite positive operating profit.
Earnings Quality
Ordinary income of 22.2B yen versus operating income of 23.7B yen indicates net non-operating costs of approximately 1.5B yen, representing 0.3% of revenue. This modest gap primarily reflects financial costs associated with increased borrowing levels, as interest-bearing debt grew substantially during the period. Non-operating expense burden remains manageable with interest coverage ratio at 10.47x (operating income to interest expense), preserving debt servicing capacity despite margin pressure. The profit before tax of 23.1B yen compared to ordinary income of 22.2B yen shows minimal extraordinary items, confirming earnings derive from core operations. However, earnings quality faces headwinds from working capital deterioration, evidenced by accounts receivable at 190 days sales outstanding and inventory at 125 days, extending the cash conversion cycle. The combination of compressed operating margins, elevated working capital requirements, and increased short-term debt dependence suggests earnings quality warrants close monitoring for cash flow sustainability.
Guidance Update
Full-year guidance projects revenue of 615.0B yen (YoY +1.5%), operating income of 34.0B yen (YoY -17.7%), ordinary income of 33.0B yen (YoY -12.7%), and net income of 23.0B yen. Q3 progress rates stand at revenue 78.5% (482.6B/615.0B), operating income 69.7% (23.7B/34.0B), and ordinary income 67.2% (22.2B/33.0B) of full-year targets. Revenue tracking slightly ahead of the standard 75% Q3 progress rate reflects seasonal patterns or steady quarterly execution. However, profit metrics lag expectations with operating income at 69.7% versus standard 75%, implying Q4 needs to deliver approximately 10.3B yen operating income, representing 43.5% of first three quarters combined, to achieve guidance. This back-end loading requires significant margin recovery through SG&A control or volume leverage in Q4. The company's maintained guidance suggests confidence in cost management initiatives or seasonal profit patterns in the final quarter.
Shareholder Returns
Annual dividend is planned at 45.0 yen per share (interim 40.0 yen, year-end 42.0 yen), representing a payout ratio of approximately 46.0% based on current net income run-rate. The dividend per share compares to full-year EPS forecast of 269.24 yen, yielding a payout ratio of 16.7% on guidance basis, suggesting the company views current quarter earnings as below normalized levels. The payout ratio based on trailing net income of 16.8B yen indicates dividends are sustainable within operating cash flow constraints, though cash coverage should be monitored given elevated working capital needs and short-term debt obligations. No share buyback activity was disclosed in the period. The dividend policy maintains shareholder returns despite profit decline, signaling management confidence in earnings recovery and cash generation capacity to support both debt service and distributions.
Risk Factors
-
Liquidity and refinancing risk: Short-term borrowings of 276.2B yen represent 92.9% of interest-bearing debt with cash coverage of only 0.25x, creating near-term maturity pressure. The 46.7% YoY increase in short-term borrowings alongside working capital expansion indicates potential cash flow strain requiring active credit facility management and rollover execution.
-
Working capital deterioration: Accounts receivable of 251.0B yen (approximately 190 days sales outstanding) and inventories of 122.4B yen (approximately 125 days) indicate extended operating cycles. Persistent working capital buildup constrains free cash flow generation and increases external financing dependence, with potential collection or obsolescence risks if market conditions soften.
-
Margin compression and cost control: Operating margin contracted 289 basis points to 4.9% as SG&A expenses grew faster than revenue, reducing profitability by 34.8% despite 3.4% sales growth. Continued cost base expansion without corresponding revenue acceleration would further pressure profitability and cash generation, challenging dividend sustainability and debt servicing capacity.
Industry Benchmark (Reference - Proprietary Data)
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates substantially stronger financial health and operational efficiency compared to pharmaceutical industry medians. Profitability metrics show significant outperformance with ROE of 4.9% versus industry median of -35.8%, operating margin of 4.9% versus -218.2%, and net profit margin of 3.5% versus -216.8%, reflecting profitable operations while many industry peers operate at losses. Financial health indicators also exceed benchmarks with equity ratio of 38.7% below but reasonable versus industry median of 67.8%, though the company carries higher leverage typical of distribution operations. Efficiency metrics reveal faster asset utilization with asset turnover of 0.54x substantially exceeding industry median of 0.17x, consistent with pharmaceutical wholesale business models versus R&D-intensive manufacturers. Working capital management shows receivables turnover of approximately 190 days compared to industry median of 151 days, indicating slightly extended collection cycles, while inventory turnover appears more efficient than the industry median of 282 days. The current ratio of 1.11x falls below the industry's highly liquid median of 6.62x, reflecting the company's wholesale distribution model with higher inventory and receivables turnover requirements versus asset-light pharmaceutical developers. Overall positioning indicates a fundamentally profitable wholesale distribution operation with solid execution relative to a pharmaceutical industry benchmark dominated by development-stage or specialty manufacturers with negative profitability profiles.
※ Industry: Pharmaceutical (13 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
Key Takeaways from Earnings
-
Profitable growth trajectory despite margin pressure: The company maintains positive profitability with ROE of 4.9%, operating margin of 4.9%, and net margin of 3.5%, substantially outperforming pharmaceutical industry peers operating at median losses. Revenue growth of 3.4% YoY demonstrates market share stability, though the 34.8% operating income decline driven by SG&A expansion represents the critical management challenge requiring operational efficiency improvements in coming periods.
-
Liquidity management as key near-term focus: Short-term borrowings surged 46.7% to 276.2B yen with cash coverage of 0.25x, creating refinancing focus alongside working capital optimization needs. Extended receivables and inventory cycles tie up approximately 374B yen in operating assets, representing 77.5% of total assets, indicating significant cash flow improvement potential through collection acceleration and inventory efficiency gains that would reduce external financing dependence and strengthen balance sheet resilience.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI Financial Analysis
Executive Summary
FY2026 Q3 performance was weak: modest revenue growth did not offset pronounced margin compression, resulting in lower operating, ordinary, and net income. Revenue increased 3.4% year on year to ¥48.27bn. Operating income fell 34.8% to ¥2.37bn, substantially underperforming top-line growth. Ordinary income declined 33.7% to ¥2.22bn. Net income decreased 29.9% to ¥1.68bn, equivalent to EPS of ¥197.24. Gross profit declined 1.0% to ¥12.52bn despite the revenue increase. The gross margin contracted by 117bp year on year to 25.9% from 27.1%, indicating that cost of sales increased faster than sales. SG&A expenses rose 12.6% to ¥10.15bn, materially outpacing revenue growth. Consequently, the SG&A-to-sales ratio increased by 172bp to 21.0%. The operating margin compressed by 289bp to 4.9% from 7.8%, placing profitability at the threshold identified by the operating-efficiency alert. Net margin fell by 166bp to 3.5% from 5.1%. The annualized DuPont ROE was 6.5%, below the 8% benchmark, with low profitability rather than leverage providing the principal constraint. A ¥0.12bn gain on sales of investment securities lifted pre-tax income, so reported net income includes a modest non-recurring contribution. The full-year sales forecast implies Q3 progress of 78.5%, modestly ahead of the standard 75% pace, while operating-income progress of 69.6% is behind pace. Full-year guidance therefore requires a meaningful Q4 recovery in operating margin, rather than simply continued sales growth. The balance sheet has become more reliant on short-term borrowing, with short-term loans rising 46.7% year on year to ¥27.62bn. The resulting refinancing and liquidity profile, together with a long cash conversion cycle, is the central financial issue to monitor.
Profitability Analysis
The annualized three-factor DuPont decomposition is 6.5% ROE = 3.5% net profit margin × 0.719x asset turnover × 2.58x financial leverage. The weakest component is the 3.5% net margin, which fell from approximately 5.1% in the prior-year period. Asset turnover is moderate, while financial leverage supports ROE but also reflects a liability-heavy capital structure. The main earnings deterioration was operating in nature: gross margin fell 117bp to 25.9%, and SG&A expenses increased 12.6% versus only 3.4% sales growth. This created 289bp operating-margin compression to 4.9%. The extended DuPont factors show a 0.730 tax burden and 0.974 interest burden, indicating that taxes and net interest had limited incremental impact on the pre-tax-to-net-income conversion; the decline originated predominantly above operating income. Interest coverage remains adequate at 10.47x, but has weakened sharply from roughly 32.7x in the prior-year period as EBIT fell and interest expense more than doubled to ¥0.23bn. Annualized ROA implied by the provided DuPont data is approximately 2.5%, also indicating limited earnings generation from the asset base. The 4.0% ROIC quality alert is consistent with this low operating return profile and is below the 5% warning threshold. For a pharmaceutical manufacturer, the sub-5% EBIT margin leaves relatively limited protection against reimbursement-price revisions, input-cost pressure, or manufacturing disruption. The sustainability of a margin rebound depends on whether cost-of-sales pressure and elevated SG&A are temporary; the reported figures currently do not demonstrate operating leverage.
Growth Assessment
Revenue growth of 3.4% to ¥48.27bn demonstrates that demand remained positive through Q3. However, growth quality weakened because gross profit fell 1.0% despite higher sales. Cost of sales rose 5.1% to ¥35.74bn, faster than revenue, driving the gross-margin decline. SG&A expense growth of 12.6% further reduced conversion of incremental revenue into operating profit. The full-year forecast calls for revenue of ¥61.50bn, up 1.5% year on year, indicating an implied moderation in Q4 sales growth. Q3 sales progress is 78.5% versus the standard 75%, so the sales target appears broadly achievable based on the cumulative run rate. In contrast, operating-income progress is 69.6% and ordinary-income progress is 67.2%, both more than 5 percentage points below the standard Q3 pace. Net-income progress is 73.2%, nearer the 75% benchmark, partly aided by the ¥0.12bn securities-sale gain. Achieving the ¥3.40bn operating-income forecast requires ¥1.03bn of Q4 operating income, compared with ¥2.37bn cumulatively through Q3. That outcome requires a clear improvement in quarterly profitability relative to the year-to-date margin. The company operates in a pharmaceutical-manufacturing environment where reimbursement pricing, procurement costs, and product-supply reliability can affect earnings conversion even when revenue is stable.
Financial Health
Liquidity is positive but tight. The current ratio is 1.11x, above 1.0x and therefore not an immediate current-liability coverage breach, but below the 1.5x healthy benchmark. The quick ratio is 0.87x, below 1.0x, meaning that liquid assets excluding inventories do not fully cover current liabilities. Working capital is positive at ¥5.66bn, but this cushion is modest relative to ¥50.98bn of current liabilities. Short-term loans total ¥27.62bn and account for 92.9% of ¥29.72bn interest-bearing debt. This short-term debt ratio is the root cause of the refinancing-risk alert: a large share of the funding structure requires regular rollover rather than being matched to long-lived assets. Cash deposits of ¥6.88bn cover only 0.25x of short-term loans, which is the root cause of the liquidity-stress alert and limits the capacity to repay debt without refinancing or operating-cash inflows. Short-term loans increased ¥8.79bn, or 46.7% year on year, while long-term loans declined to ¥2.10bn. This trend worsens maturity mismatch risk because current liabilities of ¥50.98bn are supported by current assets of ¥56.64bn, with a substantial portion of those assets represented by receivables and inventories. Debt-to-equity of 1.58x is below the 2.0x aggressive threshold, but is elevated relative to a conservative balance sheet. Debt-to-capital is 46.2%, above the 40% investment-grade benchmark but below the 60% concern threshold. Equity increased 4.9% year on year to ¥34.66bn, slower than the 12.5% increase in liabilities, reducing the equity ratio to 38.7% from 40.4%. Interest coverage of 10.47x remains a mitigating factor, although the increase in interest expense to ¥0.23bn should be monitored closely. Non-current provisions total ¥0.17bn and the provision for bonuses is ¥0.48bn.
Notable B/S Changes
Short-term loans: +¥8.79bn (+46.7%) to ¥27.62bn — increased reliance on short-term financing materially heightens refinancing and liquidity-management risk.
Cash Flow Quality
Receivables of ¥25.10bn represent 28.1% of total assets, while inventories of ¥12.24bn represent 13.7%. The high-DSO alert of 142 days indicates slow conversion of reported sales into customer collections and increases working-capital funding needs. The high-inventory-days alerts of 113 days and 94 days both point to elevated inventory holding periods under the respective alert calculations. For a pharmaceutical manufacturer, elevated finished-goods inventories can provide service-level resilience but also raise the risk of product obsolescence, expiry, and capital being tied up in stock. The 222-day cash conversion cycle is the key working-capital concern because it combines slow collections and elevated inventories, increasing dependence on short-term funding. The year-on-year decline in receivables of ¥1.39bn and inventories of ¥0.40bn is directionally constructive, but short-term loans nevertheless increased by ¥8.79bn. This divergence means refinancing needs remain material despite some balance-sheet improvement in working-capital balances. Investors should focus on whether receivable days, inventory days, and short-term borrowing decline together in subsequent periods.
Dividend Sustainability
The full-year dividend forecast is ¥90 per share, consisting of the reported ¥45 interim dividend and an implied ¥45 year-end dividend. Based on forecast EPS of ¥269.24, the forecast dividend payout ratio is approximately 33.4%, below the 60% sustainability benchmark. The reported interim-only payout ratio is 25.3% of Q3 cumulative net income. This indicates that the stated dividend level is covered by reported earnings on both a year-to-date and forecast basis. However, the ability to sustain dividends alongside debt reduction is more sensitive to liquidity than the earnings payout ratio alone, given ¥27.62bn of short-term loans and cash coverage of only 0.25x. Improvement in operating profitability and working-capital efficiency would strengthen the financial flexibility supporting the dividend policy.
Risk Assessment
Business risks include Margin risk: gross margin declined 117bp and operating margin declined 289bp to 4.9%; further cost inflation or reimbursement-price pressure would have an outsized effect on earnings., Pharmaceutical manufacturing risk: product quality, supply continuity, procurement conditions, and inventory management are important because finished goods total ¥12.24bn and inventory holding periods are elevated., Working-capital risk: DSO of 142 days, DIO alerts of 94-113 days, and a 222-day cash conversion cycle tie up capital and can delay conversion of revenue into liquidity., Forecast-execution risk: operating-income progress of 69.6% is below the normal 75% Q3 pace, requiring an improvement in Q4 profit conversion to meet full-year guidance..
Financial risks include Refinancing risk is high because 92.9% of interest-bearing debt is short term; short-term loans increased 46.7% year on year to ¥27.62bn., Liquidity stress is elevated because cash deposits cover only 0.25x of short-term loans and the quick ratio is below 1.0x., Capital efficiency remains weak, with annualized ROE of 6.5%, implied annualized ROA of approximately 2.5%, and ROIC of 4.0%., Interest-cost sensitivity has increased: interest expense more than doubled to ¥0.23bn, although interest coverage remains adequate at 10.47x..
Key concerns include Highest priority: refinancing and liquidity management, as the funding maturity structure is concentrated in short-term debt., High priority: restoration of gross margin and control of SG&A growth, since SG&A rose 12.6% against 3.4% revenue growth., High priority: reduction in the cash conversion cycle through faster collections and inventory discipline., Moderate priority: earnings quality at the pre-tax level, as a ¥0.12bn gain on sales of investment securities contributed to profit before tax..
Investment Implications
Key takeaways include Revenue growth remained positive at 3.4%, but profit conversion deteriorated materially, with operating income down 34.8%., The annualized 6.5% ROE is constrained chiefly by a 3.5% net margin and weak 4.0% ROIC rather than by insufficient leverage., Short-term borrowing increased to ¥27.62bn, making liquidity management and debt rollover central to the financial profile., Full-year revenue guidance is broadly supported by Q3 progress, whereas operating-profit guidance requires a Q4 margin recovery., The ¥90 forecast DPS implies a moderate 33.4% forecast payout ratio, but balance-sheet flexibility remains more important than payout coverage alone..
Metrics to watch include Operating margin and gross margin, particularly whether they recover from 4.9% and 25.9%, respectively., SG&A growth relative to sales growth., Short-term loans, cash-to-short-term-debt coverage, current ratio, and quick ratio., DSO, inventory days, and the cash conversion cycle., Q4 operating income versus the ¥1.03bn implied amount needed to achieve the ¥3.40bn full-year forecast., Interest expense and interest coverage..
Regarding relative positioning, The company presents a low-margin, capital-intensive pharmaceutical-manufacturing profile, with profitability and ROIC below the cited benchmarks. Adequate interest coverage and a forecast payout ratio below 60% are offsets, but the short-term-debt concentration and extended working-capital cycle create a more financially constrained profile than a conservatively funded peer.